EBD Group is part of the KNect365 of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnerships in Cell and Gene Therapy Partnerships in Cell and Gene Therapy Partnerships in Cell and Gene Therapy Partnerships in Cell and Gene Therapy
Share/Follow Us
Share this:
Follow this event:
Subscribe to our newsletters:

Partnerships in Cell and Gene Therapies Program Overview


Programs throughout the year will cover:

  • Translational research for early stage opportunities
  • Developing sustainable commercial strategies
  • Regulatory environment
  • Funding models
  • Collaborations and partnership approaches
  • Regional business development opportunities
  • Cell therapy including stem cells and immunotherapy
  • Gene therapy and genome editing
  • Tissue engineering
  • Bioprocessing and biomaterials
  • Devices

Monday, April 4, 2016
Partnerships in Regenerative Medicine and Advanced Therapies
Cell therapies: The panacea for all that ails us
Level 0, Room E5

We have seen exciting advances in this field but what will it take to bring cures to the market? The emergence of new technologies to potentially treat neurological, immunological, and genetic diseases is promising but there are many pitfalls. This session will discuss the clinical, manufacturing, and regulatory pathways towards realizing the promise of these therapies.

Phil Vanek – GM, Cell Therapy Technologies, GE Healthcare

  • Thomas Liénard – Chief Business Officer, Bone Therapeutics SA
  • Miguel Mulet – Director, Strategy and New Projects, TiGenix NV
  • Georges Rawadi – VP, Business Development, Celyad
  • Jeff Till – Director, External Innovation, Merck
Share this:Email this pageShare this on LinkedInShare this on Twitter
Targeted cancer therapies: Breakthroughs in new treatments
Level 0, Room E5

With the advances in immunotherapies, we have seen more partnerships, IPOs, and clinical developments than ever before. Whether through checkpoint inhibitors, combination therapies, or CAR-T therapies, there is much to be excited about. We will highlight the newest breakthroughs and explore what's in the pipeline that has the industry buzzing.

Mike Ward – Global Director of Content, Informa Pharma Insights

  • Iain Dukes – Senior VP, Business Development and Licensing, MSD
  • Kevin Foote – Director External Projects, iMed Oncology, AstraZeneca
  • Philippe Lopes-Fernandes – Senior VP, Head, Global Business Development and Alliance Management, Merck
  • Olav Zilian – Senior VP, Corporate Development, Medigene AG
Share this:Email this pageShare this on LinkedInShare this on Twitter
Advanced therapies: The keys to treating rare diseases
Level 0, Room E5

In treating Duchenne Muscular Dystrophy, Huntington's disease, cystic fibrosis, and other rare diseases, we are seeing new technologies transforming the treatment landscape. Hear from the leading companies as they discuss the promising advances that may not only treat but possibly cure these rare disorders.

David Greenwald – Director, Business Development, Johns Hopkins Technology Ventures

  • Jaap de Boer – Director, Scientific Development and Alliance Management, Business Operations Europe, Sanofi Genzyme
  • Stephen James – VP, Head of Research and Drug Design and Development, Swedish Orphan Biovitrum AB (Sobi)
  • Christian Meyer – Chief Medical Officer, UniQure
  • Yael Weiss – Executive Director, Business Development, Ultragenyx Pharmaceutical
Share this:Email this pageShare this on LinkedInShare this on Twitter
It's not a mirage: The promise of cell and gene therapy is real
Level 0, Room E5

How will the landscape change as more diseases have the potential to be treated or even cured with the advances in this field? What will it take to make these promises into a reality? Pharma execs will share insights on their strategies in developing, manufacturing, and commercializing these life-changing treatments.

Morrie Ruffin – Managing Partner, Adjuvant Partners

  • Vered Caplan – CEO, Orgenesis
  • John McDonald – VP, Business Development, Biogen
  • Alexandra Richardson – Head, Business Development, Clayton Biotechnologies, Inc.
  • Jason Slingsby – Head, Business Development, Oxford BioMedica
Share this:Email this pageShare this on LinkedInShare this on Twitter
Arrow Up

Follow this event:
Home | Contact Us | Site Map
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2016 EBD Group
Privacy Policy and Cookies
Terms of Use